Targeting of systemically-delivered magnetic nanoparticle hyperthermia using a noninvasive, static, external magnetic field

One of the greatest challenges of nanoparticle cancer therapy is the delivery of adequate numbers of nanoparticles to the tumor site. Iron oxide nanoparticles (IONPs) have many favorable qualities, including their nontoxic composition, the wide range of diameters in which they can be produced, the cell-specific cytotoxic heating that results from their absorption of energy from a nontoxic, external alternating magnetic field (AMF), and the wide variety of functional coatings that can be applied. Although IONPs can be delivered via an intra-tumoral injection to some tumors, the resulting tumor IONP distribution is generally inadequate; additionally, local tumor injections do not allow for the treatment of systemic or multifocal disease. Consequently, the ultimate success of nanoparticle based cancer therapy likely rests with successful systemic, tumor-targeted IONP delivery. In this study, we used a surface-based, bilateral, noninvasive static magnetic field gradient produced by neodymiumboron- iron magnets (80 T/m to 130 T/m in central plane between magnets), a rabbit ear model, and systemicallydelivered starch-coated 100 nm magnetic (iron oxide) nanoparticles to demonstrate a spatially-defined increase in the local tissue accumulation of IONPs. In this non-tumor model, the IONPs remained within the local vascular space. It is anticipated that this technique can be used to enhance IONP delivery significantly to the tumor parenchyma/cells.

[1]  D. Huhn,et al.  Preclinical experiences with magnetic drug targeting: tolerance and efficacy. , 1996, Cancer research.

[2]  E P Furlani,et al.  Analytical model of magnetic nanoparticle transport and capture in the microvasculature. , 2006, Physical review. E, Statistical, nonlinear, and soft matter physics.

[3]  K. B. Ocheltree,et al.  Determination of power deposition patterns for localized hyperthermia: a steady-state analysis. , 1987, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[4]  H. Bagaria,et al.  Transient solution to the bioheat equation and optimization for magnetic fluid hyperthermia treatment , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[5]  Edward P. Furlani,et al.  Magnetic Biotransport: Analysis and Applications , 2010, Materials.

[6]  Florence Gazeau,et al.  Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. , 2006, Radiology.

[7]  P Reichardt,et al.  Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. , 1996, Cancer research.

[8]  H. Knoepfel Magnetic Fields: A Comprehensive Theoretical Treatise for Practical Use , 2000 .

[9]  R Ivkov,et al.  Assessment of intratumor non-antibody directed iron oxide nanoparticle hyperthermia cancer therapy and antibody directed IONP uptake in murine and human cells , 2009, BiOS.

[10]  C. Driscoll,et al.  Magnetic targeting of microspheres in blood flow. , 1984, Microvascular research.

[11]  Carl K. Hoh,et al.  Targeting and retention of magnetic targeted carriers (MTCs) enhancing intra-arterial chemotherapy , 1999 .